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Abstract
Introduction: Systemic lupus erythematosus (SLE) is characterized by frequent neuropsychiatric involvement, which
includes cognitive impairment (CI). We aimed at assessing CI in a cohort of Italian SLE patients by using a wide range of
neurocognitive tests specifically designed to evaluate the fronto-subcortical dysfunction. Furthermore, we aimed at testing
whether CI in SLE is associated with serum autoantibodies, disease activity and chronic damage.
Methods: Fifty-eight consecutive patients were enrolled. Study protocol included data collection, evaluation of serum levels
of ANA, anti-dsDNA, anti-cardiolipin, anti-b2-glycoprotein I, anti-P ribosomal, anti-endothelial cell, and anti-Nedd5
antibodies. SLEDAI-2000 and SLICC were used to assess disease activity and chronic damage. Patients were administered a
test battery specifically designed to detect fronto-subcortical dysfunction across five domains: memory, attention, abstract
reasoning, executive function and visuospatial function. For each patient, the raw scores from each test were compared
with published norms, then transformed into Z scores (deviation from normal mean), and finally summed in the Global
Cognitive Dysfunction score (GCDs).
Results: Nineteen percent of patients had mild GCDs impairment (GCDs 2–3), 7% moderate (GCDs 4–5) and 5% severe
(GCDs$6). The visuospatial domain was the most compromised (MDZs=20.8961.23). Anti-cardiolipin IgM levels were
associated with visuospatial domain impairment (r=0.331, P=0.005). SLEDAI correlated with GCDs, and attentional and
executive domains; SLICC correlated with GCDs, and with visuospatial and attentional domains impairment.
Conclusions: Anti-phospholipids, disease activity, and chronic damage are associated with cognitive dysfunction in SLE. The
use of a wide spectrum of tests allowed for a better selection of the relevant factors involved in SLE cognitive dysfunction,
and standardized neuropsychological testing methods should be used for routine assessment of SLE patients.
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Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease
characterized by frequent neuropsychiatric involvement that could be
found up to 80% of patients [1–7]. Neuropsychiatric SLE (NPSLE)
includes a wide range of neurological and psychiatric manifestations as
well as cognitive impairment (CI). In 1999, the American College of
Rheumatology (ACR) proposed a standard nomenclature for NPSLE
with case definitions for nineteen neuropsychiatric syndromes
associated with SLE [1]. So far, there is no reliable diagnostic test,
which makes the diagnosis of NPSLE difficult. Manifestations of
NPSLE vary in severity, ranging from mild headache to life-
threatening coma [8]. Advances in research methodologies and the
introduction of neuropsychological methods have improved clinicians’
ability to identify CI in both pediatric and adult SLE patients [9].
CI in SLE is characterized by deficits in attention, learning and
recall, verbal and nonverbal fluency, language, visuospatial skills,
executive functions and motor dexterity and is probably due to a
damage of fronto-subcortical circuits [4–6]. The prevalence of CI
in SLE patients was found to be comprised between 3–80% of
patients [10–14].
This apparent discrepancy is mainly due to the different tests
that were administered in these studies, and by the above-
mentioned only recent application of a specific nomenclature for
CI in SLE patients. Petri et al. in 2008 found that after adjusting
for age, gender, ethnicity, and education, SLE patients score
significantly lower than controls on measures of cognitive
efficiency requiring sustained attention/vigilance, visuospatial
span of attention/working memory, and simple reaction time
[15]. Nonetheless, it was showed that CI in children and
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ment, arithmetic, reading comprehension, learning, visual mem-
ory and complex problem solving ability [16].
The pathogenesis of NPSLE has been attributed to autoanti-
body-mediated neuronal dysfunction, vasculopathy, and coagu-
lopathy [17–19]. It has been suggested that several autoantibody
specificities may play a role in the pathogenesis of NPSLE
[reviewed in 20]. Among others, a potential pathogenic relevance
has been attributed to anti-neuronal, anti-P ribosomal proteins,
anti-phospholipids (aPL), and human N-methyl-D-aspartate
(NMDA) receptor types NR2a or NR2b (anti-NR2) antibodies
[20–29]. Recently, we demonstrated an association between the
presence of anti-endothelial-cell antibodies (AECAs) and anti-
Nedd5 C-ter antibodies with psychiatric manifestations, such as
psychosis and depression, in SLE [24,25]. In 1999, the ACR Ad
Hoc Committee on Neuropsychiatric Lupus nomenclature
proposed a brief research battery of neurocognitive tests to
quantify cognitive dysfunction in SLE [1]. In 2007 the response
criteria for neurocognitive impairment in SLE clinical trials were
proposed, and the combination of the ACR neuropsychological
battery with the Cognitive Symptoms Inventory (CSI) [30] was
suggested to evaluate cognitive function [1,31]. The objective of
the present study was to assess cognitive dysfunction in a cohort of
Italian SLE patients by using a wide range of neurocognitive tests,
including those from the ACR and the CSI, specifically designed
to evaluate the fronto-subcortical dysfunction typical of NPSLE.
Furthermore, we aimed at testing whether CI in NPSLE was
associated with serum autoantibodies, including anti-dsDNA, aPL,
AECA, anti-Nedd5, and anti-P ribosomal, and with disease
activity and chronic damage.
Materials and Methods
Fifty-eight consecutive patients $16 years of age affected with
SLE, as diagnosed according to the ACR revised criteria [32],
were enrolled in this cross-sectional study at the Lupus Clinic,
Sapienza University of Rome. Written informed consent was
obtained from each patient and the ethic committee of Sapienza
Universita ` di Roma approved the study design.
Study protocol included complete physical examination and
blood drawing. The clinical and laboratory data were collected in
a standardized computerized electronically-filled form including
demographics, past medical history with date of diagnosis, co-
morbidities, and previous and concomitant treatments. Clinical
activity was assessed using the SLE Disease Activity Index
(SLEDAI) [33], while chronic damage was evaluated using the
Systemic Lupus International Collaborative Clinics/American
College of Rheumatology (SLICC/ACR) Damage Index
[34,35]. Each subject underwent peripheral blood sample
collection. The sera recovered were then stored at 220uC until
assayed.
Methods of assessment of AECA and anti-Nedd5 antibodies
have been previously described [24,25]. In brief, human umbilical-
vein endothelial cells were isolated by collagenase perfusion from
normal-term umbilical cord veins [36] and were cultured in M19
medium (Sigma Chemical Co, St. Louis, MO, USA) supplement-
ed with 20% FCS. These cells (third to fourth passage) were used
to detect AECA of IgG isotype using a cell-surface ELISA on
living cells allowed to grow to confluence in microtiter plates. After
three washes with Hank’s balanced salt solution (HBSS),
nonspecific binding sites were blocked for 2 hours at room
temperature with 3% bovine serum albumin (BSA)/HBSS. After
two washes with HBSS, the wells were incubated in duplicate with
100 ml of the sera diluted 1:50 in HBSS for 2 hours at room
temperature. After three washes with HBSS, the bound antibodies
were detected with alkaline-phosphatase-conjugated goat antibod-
ies antihuman IgG (Sigma), using 1 mg/ml p-nitrophenylpho-
sphate. Optical density (OD) was measured at 405 nm wavelength
and AECA were expressed as a binding index (BI), equal to
1006(S-A)/(B-A), where S is the OD of the sample tested, A is the
OD of a negative control, and B that of a positive reference serum.
AECA were considered positive when the BI was higher than the
cutoff value (mean+2 standard deviations (SD) of 66 healthy
controls) corresponding to 50% of a positive reference serum from
an SLE patient [36].
ELISA for specific total anti-Nedd5 IgG was developed as
previously described [25]. Briefly, polystyrene plates (Dynex,
Berlin, Germany) were coated with Nedd5 C-ter 0.5 mg/well in
0.05 mM NaHCO3 buffer, pH 9.5. Coated plates were incubated
overnight at 4uC and then washed three times with PBS
containing 0.05% Tween-20 in an automated washer (Wellwash
4, Labsystem, Turku, Finland). Plates were blocked with PBS
Tween containing 3% gelatin (Bio-Rad), 100 ml/well, for 1 hour
at room temperature and washed as previously described [25].
Human sera were diluted in PBS Tween-20 and 1% gelatin (1:100
for total IgG) and pipetted onto plates at 100 ml per well. Plates
were incubated for 1 hour at 20uC and washed as described.
Peroxidase-conjugated goat antihuman IgG (Bio-Rad) was diluted
1:3000 in the same buffer. These dilutions were used as second
antibodies and incubated (100 ml/well) for 1 hour at 20uC. o-
Phenylenediamine dihydrochloride (Sigma) was used as a substrate
and absorbance was measured at 490 nm. Means+2 SD of the
absorbance reading of the 66 healthy controls were considered the
cutoff levels for positive reactions. All assays were performed in
quadruplicate. Data were presented as the mean OD corrected for
background (wells without coated antigen). The results of
unknown samples on the plate were accepted if internal controls
(two serum samples, one positive and one negative) had an
absorbance reading within mean 610% of previous readings. To
inhibit specific IgG, the sera from three patients with SLE, IgG
anti-Nedd5 positive, were diluted 1:50 in PBS-Tween and were
incubated overnight at room temperature in 10 mg/ml of Nedd5
C-ter according to the method reported by Huang and colleagues
[25]. As a negative control, the sera were pre-incubated with
40 mg/ml of BSA.
Anti-cardiolipin (anti-CL), anti-P ribosomal proteins (P0, P1),
and anti-b2 glycoprotein I (GPI) ELISA kits were obtained from
Diamedix (Miami, FL, USA, 30). Anti-CL of IgG and/or IgM
isotype as well as anti-b2GPI of IgG and/or IgM isotype in serum
were expressed as immunoglobulin G phospholipid (GPL) or
immunoglobulin M phospholipid (MPL) units using international
reference material and considered positive at a titer .20 GPL or
MPL. Anti-dsDNA antibodies were performed in indirect
immunofluorescence in accordance with the manufacturer’s
instructions. All assays were performed in duplicate. A positive
control and several normal human sera were run in the same assay
to confirm the specificity of the results. Levels of aPL, anti-P
ribosomal, AECA and anti-Nedd5 were categorized as absent (Z
score,1), low (Z score between 1 and 2), or high (Z score.2) after
comparison with healthy controls, as previously described [26].
All patients underwent an extensive cognitive-behavioral
neuropsychological assessment. Neurocognitive assessment was
performed during a 1-hour interview and included standardized
testing for 5 domains: memory, attention, abstract reasoning,
executive and visuospatial functions. This assessment included
those tests from the ACR and the CSI standardized in an Italian
population, and was specifically designed to detect the fronto-
subcortical dysfunction typical of SLE.
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Personality Inventory (MMPI) to exclude that cognitive dysfunc-
tion could be related to behavioral abnormalities [37]. We used
the following tests: Mini Mental State Examination for general
cognitive status - Rey Auditory Verbal Learning Test and Digit
Span forward, two efficient neuropsychological instruments for
testing verbal memory – Immediate Visual Memory Test (an
Italian visuospatial test) and Corsi Block-Tapping Test forward,
used to measure visuospatial memory - Copying of Drawings with
and without elements of programmation, two common tools to
evaluate visuospatial abilities - Attentive Matrices for both selective
and sustained attention - Raven’s Progressive Matrices, a widely
used non verbal intelligence test for abstract reasoning - Digit
Span backward, Corsi Block-Tapping Test backward, Phonolog-
ical Verbal Fluency Test, Trail Making Test A, Trail Making Test
B, Wisconsin Card Sorting Test, Analogies Test and Time and
Weight Estimation Test, STEP, to investigate deeply the presence
of executive dysfunctions [38–42].
Unadjusted analysis was performed as previously described
[26]. Briefly, for each patient, the raw scores from each test were
compared with published norms (age-, sex-, and education level-
corrected, when necessary) and transformed into Z scores to
express the deviation from the normal mean [Z=(raw data2test
mean)/test standard deviation] [26]. Mean domain Z scores
(MDZs) were defined as the average of the Z scores from the tests
comprising each domain. To indicate cognitive function as a
composite score, the Z score for each domain was transformed
into a Domain Cognitive Dysfunction score (DCDs), with higher
values representing more impairment in a particular domain. The
sum of all DCDs across the 5 domains resulted in the Global
Cognitive Dysfunction score (GCDs), which was transformed into
a Global Cognitive Dysfunction category (GCDc) (Table 1).
The statistical calculations were performed using Statistical
Package for Social Sciences 13.0 (SPSS, Chicago, IL, USA) and
GraphPad 5.0 (La Jolla, CA, USA). Normally distributed variables
were summarized using the mean 6 SD, and non-normally
distributed variables by the median and range. Wilcoxon’s matched
pairs test and paired t-test were performed. Univariate comparisons
between nominal variables were calculated using chi-square (x
2)t e s t
or Fisher-test where appropriate. Two-tailed P values were reported,
P values less than or equal to 0.05 were considered significant.
GCDs were compared in patients grouped by antibody level. The
binary outcomes variable for the antibody testing were serum
autoantibody status, defined either as present versus absent or low/
absent versus high. The results were verified through analysis of the
domain Z scores and single-test Z scores. Descriptive statistics were
computed for all study variables. Multivariable logistic regression
analysis was performed to explore any effect of anti-cardiolipin IgM,
sex, age, educational level, SLEDAI, SLICC, and corticosteroid
dosage on GCD. In this regression, only variables that achieved P
value,0.100 inthe univariate analysis were included for calculation.
Results
Clinical and demographic features of the patients are shown in
Table S1. All the patients, were Caucasian and showed a relatively
high level of education (mean 12.1 years), thus an expected
relatively high level of cognitive function. At the time of study
entry, mean daily prednisone dosage was relatively low and a
notable percentage (22.4%) was taking no steroids, in accordance
with the high number of patients with low disease activity or with
complete remission (Table S1).
When considering the patients’ mean domain Z scores, visuospa-
tial domain was the most compromised (MDZs=20.8961.23), and
it was the only test in the mildly impaired range (Z score of 20.6 or
less), as shown in Figure 1.
After transforming the MDZs into DCDs (Table 1), the
percentage of patients with impairment in the diverse domains
was calculated as shown in Table 2. Again, the visuospatial
domain showed the highest percentages of patients with some CI.
Considering the GCDs, 11 patients (19%) had mild GCDs
impairment (GCDs 2–3), 4 patients (7%) showed moderate
impairment (GCDs 4–5) and 3 patients (5%) had severe
dysfunction (GCDs$6). Fourteen patients (24.1%) showed path-
ological MMPI. However, when comparing patients with MMPI
impairment and those without, there were no significant
differences in GCDs (2.362.7 vs 1.161.5, respectively, P=0.868).
Anti-CL IgM were present in 6 (10.3%) patients, anti-CL IgG in
7 (12.1%), anti-b2GPI IgM in 6 (10.3%), anti-b2GPI IgG in 7
(12.1%), anti-P ribosomal in 12 patients (20.2%), AECA in 6
patients (10.3%), and anti-Nedd5 in 15 (28.8%).
Within the autoantibodies tested, aCL IgM were associated with
impairment in the visuospatial domain (x
2=8.658; P=0.013).
Univariate analysis of the correlation between anti-phospholipid
antibodies with cognitive function is reported in Table 3.
No further association, neither correlation, was found with the
other autoantibody tested (anti-dsDNA, anti-P ribosomal, AECA,
anti-Nedd5).
Table 1. Scoring and categorization of cognitive dysfunction*.
Test raw scores Obtained from performance on the neurocognitive testing
Test Z scores Compared with age- and sex-matched published normal values
Mean Domain Z scores (MDZs) Average of the Z scores in the tests comprising each domain
Domain Cognitive Dysfunction Score (DCDs) 1) if MDZs$21, then DCDs=0;
2) if 22#MDZs,21, then DCDs=1;
3) if MDZs,22, then DCDs=2;
Global Cognitive Dysfunction Score Sum of Domain Cognitive Dysfunction Scores over the 5 domains (max 10)
Global Cognitive Category Defined from Global Cognitive Dysfunction Score (GCDs)
Absent GCDs 0–1
Mild GCDs 2–3
Moderate GCDs 4–5
Severe GCDs$6
*The composite score is constructed from the bottom to the top of the table.
doi:10.1371/journal.pone.0033824.t001
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SLEDAI and SLICC with cognitive function is reported in
Table 4.
No further correlation was found with the other clinical features
tested (age, sex, disease duration, prednisone dosage).
The statistical significance of such correlations remained also
when adjusted for age, sex, and steroid therapy. In the logistic
regressionanalysis, GCD wasinverselyassociatedwiththe education
level (P=0.025), while no effect was found for anti-cardiolipin IgM,
sex, age, SLEDAI, SLICC, and corticosteroid dosage.
Discussion
Cognitive dysfunction is common in patients with SLE, and
several studies pointed out the relevance of such problem on
patients’ health-related quality of life, functional outcome, and
employment [38]. We found CI in a relevant percentage of Italian
SLE patients, with an overall prevalence of 31% (19% mild, 7%
moderate and 5% severe), a prevalence in the average when
compared with results from previous studies that ranged between
6% and 79% [4,10–14,26]. Indeed, the prevalence of CI greatly
varied between different cohorts. Sanna et al. and Hanly et al.
reported the lowest percentages (11% and 6%, respectively)
[11,43]; however, their results could have been affected by the
retrospective study design. Nonetheless, results from our cohort
are lower than that from other Italian populations. Afeltra et al.
reported in 2003 a prevalence of 52% of CI, which was
significantly associated with higher levels of anti-PL antibodies
[12]. Probably, our results may reflect the high education level and
the low levels of disease activity observed in our cohort. The
visuospatial domain was the most affected in the present study,
suggesting a fronto-parietal deficit. In addition, any level of CI was
observed across the 5 domains in a notable percentage of patients.
The presence of behavioral abnormalities in a relevant percentage
of our patients (24%) evaluated with MMPI test, did not alter the
significance of our results. Indeed, these patients showed mean
GCDs levels similar to those without MMPI impairment.
According to previous reports [44], we found an association
between anti-PL and cognitive dysfunction, specifically visuospa-
tial domain, in SLE patients. Furthermore, education, disease
activity and chronic damage positively correlated with impairment
in cognitive functions.
Since the first report from Hanly et al., the role of anti-CL
antibodies in CI has been explored leading to conflicting results
Figure 1. Distribution of neurocognitive impairment, expressed as MDZ scores±SD, in the patients enrolled (Memory MDZ
20.03±0.84, attention MDZ 20.3±0.87, abstract reasoning 0.23±1.1, executive MDZ 20.26±0.97, visuospatial MDZ 20.87±1.24).
doi:10.1371/journal.pone.0033824.g001
Table 2. Percentage of patients with neurocognitive
impairment, expressed as DCDs, in the diverse domains
considered.
Memory Attention
Abstract
reasoning Executive Visuospatial
DCDs=0 90% 82% 85% 83% 58%
DCDs=1 5% 15% 10% 10% 27%
DCDs=2 5% 3% 5% 7% 15%
DCDs: Domain Cognitive Dysfunction score.
doi:10.1371/journal.pone.0033824.t002
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normal elderly persons may be associated with subtle neuropsy-
chological dysfunction [45]. Again, Hanly et al. suggested that
anti-CL IgG and IgA may be responsible for long-term subtle
deterioration in cognitive function in patients with SLE [13]. Anti-
PL may provoke CNS damage by several mechanisms, for
example, by modulating neuronal functions or by directly causing
thrombosis within vessels of minute caliber [46]. Moreover, anti-
PL may contribute to neurological damage by reacting with brain
cells (astrocytes, neuronal cells, and endothelial cells) by means of
b2GPI interactions as previously demonstrated by our group,
suggesting that these cells may represent the autoantibody target
[47–49]. Shoenfeld et al. administered intracerebro-ventricularly
(ICV) immunoglobulins (IgG) from patients with APS to mice,
demonstrating a direct binding to neuronal structures in the
hippocampus and cerebral cortex. Furthermore, these mice
injected with IgG performed worse in the water maze compared
to the controls [50]. It was also showed that when female BALB/c
mice were immunized once with b2-GPI in complete Freund’s
adjuvant (CFA) or with CFA alone (controls), the APS mice
develop elevated levels of antibodies against negatively charged
phospholipids and b2-GPI, accompanied by neurological impair-
ment consisting of both cognitive and behavioral changes [51].
Herein, we demonstrated the association between cognitive
dysfunction and anti-CL in a cohort of patients without a history
of cerebral thromboses. This evidence may suggest that anti-CL
may have worked by modulating neuronal function rather than
directly provoking thrombosis. Interestingly, the results showed
that the visuospatial domain impairment was also correlated with
serum anti-CL IgM titers, suggesting a potential pathogenic role of
these antibodies in brain areas related with working-memory.
The other autoantibodies tested were not found associated with
CI. Concerning anti-dsDNA and anti-P ribosomal, we can
consider our result as a confirmation of previous studies
[20,52,53]. Furthermore, for the first time we studied whether
AECA and anti-Nedd5 C-ter were associated with cognitive
dysfunction in SLE. These antibodies have been previously
associated with other manifestations of NPSLE [24,25,54], and a
relationship was found between AECA and anti-Nedd5 C-ter with
psychosis and depression in SLE patients [24,25]. In our cohort,
no association was found between these autoantibodies and CI. It
is interesting to note that anti-P ribosomal antibodies, which have
been mostly associated with NPSLE psychosis [53], were not
associated with CI in the present study.
It is not surprising that cognitive deficiency is associated with
lower education level, disease activity and chronic damage in
NPSLE patients. Poorer education per se may account for lower
scores in neurocognitive test batteries [55]. The association
between disease activity and CI is still uncertain. Carbotte et al.
did not demonstrate this association in an investigation performed
in 1995 [56]. However, this study had some limitations: the disease
activity was assessed using the Lupus Activity Criteria Count in all
patients while the SLEDAI was used only in a subset of twenty of
them, and a relevant percentage of these patients also had CNS
involvement at the time of the study. In contrast with Carbotte’s
results and similar to ours, Mikdashi & Handwerger in 2004
Table 3. Univariate analysis of the correlation between anti-phospholipids antibodies in SLE patients with neurocognitive
assessment.
Neurocognitive assessment
Paerson’s
Significance anti-CL IgM (MPL) anti-CL IgG (GPL) anti-b2IgM (MPL) anti-b2IgG (GPL)
Memory MDZs r 0.027 0.210 0.143 0.171
P value 0.847 0.139 0.311 0.231
Attentional MDZs r 0.050 0.348 0.214 0.230
P value 0.725 0.012 0.128 0.104
Abstract reasoning MDZs r 20.024 0.138 0.054 0.142
P value 0.868 0.334 0.702 0.321
Executive MDZs r 0.068 0.371 0.164 0.341
P value 0.634 0.007 0.246 0.014
Visuospatial MDZs r 20.148 0.182 0.009 0.220
P value 0.294 0.201 0.948 0.121
Memory DCDs r 20.095 20.056 20.088 20.055
P value 0.502 0.697 0.537 0.702
Attentional DCDs r 20.010 20.094 20.088 20.093
P value 0.942 0.510 0.535 0.518
Abstract reasoning DCDs r 0.033 20.082 20.053 20.081
P value 0.817 0.567 0.709 0.574
Executive DCDs r 0.010 20.082 20.021 20.081
P value 0.943 0.567 0.880 0.574
Visuospatial DCDs r 0.283 20.155 0.065 20.152
Pv a l u e 0.042 0.278 0.648 0.287
GCDs R 0.101 20.143 20.037 20.140
P value 0.475 0.317 0.793 0.326
MDZs: Mean Domain Z score; DCDs: Domain Cognitive Dysfunction score; GCDs: global cognitive dysfunction score.
doi:10.1371/journal.pone.0033824.t003
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an independent predictor of CI in SLE patients [19]. As
mentioned above, our patients had an overall low disease activity
(SLEDAI#4 in 86.2%), in a percentage similar to that from other
studies. Interestingly, our patients with active disease (SLEDAI.4)
showed poorer performance in specific areas (attention and
executive domains) than the group with inactive disease at the
time of testing. Therefore, it seems that cognitive dysfunction in
SLE patients may reflect an immune-mediated compromise of an
underlying neuronal substrate possibly impaired by some non-
specific effects of active illness affecting specific neurocognitive
domains.
One of the concerns in testing CI in SLE patients is the
possibility that symptoms are often fluctuating and sometimes
evanescent. Furthermore, the assessment of CI has often not been
exhaustive in early studies. Only recently the ACR has proposed a
brief but standardized research battery [1]. We used an extensive
battery of tests that deeply explore cognitive functions and allow
for the proper selection of the relevant factors involved in the
development of CI in our NPSLE patients. Our study design used
an a priori grouping of test batteries to reflect dysfunction in
different cognitive domains, employed a system in which domain
Z scores were transformed into the DCDs and further into the
composite score - the GCDs. This approach enabled us to
compare patients with severe abnormalities in one or two domains
with patients showing mild or moderate changes in several
domains. We adopted and successfully reproduced this method
from Lapteva et al, who consistently used this approach and
showed its validity [26].
In conclusion, anti-PL, disease activity, chronic damage and
educational level are associated with cognitive dysfunction in SLE.
The use of a wide spectrum of tests allowed for a better selection of
the relevant factors involved in SLE cognitive dysfunction, and
standardized neuropsychological testing methods should be used
for routine assessment of SLE patients.
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